Quoin Pharmaceuticals, Ltd. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Quoin Pharmaceuticals, Ltd. on November 5, 2023, regarding corporate actions approved by the Board of Directors and shareholders. The company is incorporated in Israel and its American Depositary Shares (ADS) trade on The Nasdaq Stock Market under the symbol QNRX.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure modifications.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-60,000 reverse split of ordinary shares, effective November 8, 2023.
- Share Capital Adjustment: Following the reverse split, the registered share capital will be reduced from 6,000,000,000,000 ordinary shares to 100,000,000 ordinary shares.
- ADS Conversion: Prior to the split, one ADS represented 60,000 ordinary shares. Effective November 8, 2023, one ADS will represent one ordinary share.
- Executive Compensation Vote Frequency: Shareholders approved conducting advisory votes on executive compensation every three years.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management outlook, or discuss specific risks and contingencies beyond the implementation of the reverse split and the change in voting frequency.
Key Facts for Investor Verification
- Verify the effective date of the reverse split is November 8, 2023.
- Confirm the new ratio of one ADS to one ordinary share post-split.
- Check the updated number of authorized ordinary shares (100,000,000) in subsequent filings.
- Note that the next advisory vote on executive compensation will occur in three years.